Fracture Risk and Zoledronic Acid Therapy in Men with OsteoporosisSteven Boonen, Eric Orwoll, Oscar Antúnez et al.|New England Journal of Medicine|2012Cited by 361
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al.|The Lancet Diabetes & Endocrinology|2019Cited by 171
Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM StudyMichael A. Bolognese, Cesar Libanati, Christence Stubbe Teglbjærg et al.|Journal of Clinical Densitometry|2012Cited by 64
In postmenopausal women with osteoporosis, denosumab significantly improved trabecular bone score (TBS), an index of trabecular microarchitectureMichael R. McClung, Cesar Libanati, Kurt Lippuner et al.|IRIS|2012Cited by 6
Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)McClung, A. Lombardi, Bente Langdahl et al.|Open Repository and Bibliography (University of Liège)|2015Cited by 3